Literature DB >> 11123867

Chemotherapy for advanced or recurrent carcinoma of the cervix.

J D Bloss1.   

Abstract

The management of early-stage cervical cancer involves primarily surgery and/or chemoradiotherapy. When the disease spreads beyond the cervix but remains confined to the pelvis and draining lymph node basins, the mainstay of management is chemoradiotherapy. The use of primary systemic chemotherapy is related to the management of disease that has recurred or spread beyond the pelvic radiation fields. Although the optimal chemotherapy regimen remains to be determined, current protocols and the associated research to support their use are discussed in this review. Additionally, the rationale for use of chemoradiotherapy in locally advanced disease is presented.

Entities:  

Mesh:

Year:  2001        PMID: 11123867     DOI: 10.1007/s11912-001-0040-5

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  95 in total

1.  Phase II trial of dichloromethotrexate in patients with advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study.

Authors:  J A Roberts; J A Blessing; R McGehee; J Beecham; H D Homesley
Journal:  Cancer Treat Rep       Date:  1987-12

2.  Phase II clinical study of Yoshi 864 in squamous cell carcinoma of the uterine cervix.

Authors:  M Slavik; H Muss; J A Blessing
Journal:  Cancer Treat Rep       Date:  1983-02

3.  Phase II trial of etoposide in the management of advanced or recurrent non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study.

Authors:  R E Slayton; J A Blessing; H D Homesley
Journal:  Cancer Treat Rep       Date:  1984-12

4.  Comparison of the therapeutic effects of adriamycin alone versus adriamycin plus vincristine versus adriamycin plus cyclophosphamide in the treatment of advanced carcinoma of the cervix.

Authors:  H J Wallace; M M Hreshchyshyn; G D Wilbanks; R C Boronow; W C Fowler; J A Blessing
Journal:  Cancer Treat Rep       Date:  1978-10

5.  Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity.

Authors:  G G Steel; M J Peckham
Journal:  Int J Radiat Oncol Biol Phys       Date:  1979-01       Impact factor: 7.038

6.  Phase II experience with ifosfamide/mesna in gynecologic malignancies: preliminary report of Gynecologic Oncology Group studies.

Authors:  G P Sutton; J A Blessing; G Photopulos; M L Berman; H D Homesley
Journal:  Semin Oncol       Date:  1989-02       Impact factor: 4.929

7.  Phase II trial of bleomycin, ifosfamide, and carboplatin in metastatic cervical cancer.

Authors:  A M Murad; S A Triginelli; J C Ribalta
Journal:  J Clin Oncol       Date:  1994-01       Impact factor: 44.544

8.  Bleomycin-ifosfamide-cis-platinum (BIP) in pelvic recurrence of previously irradiated cervical carcinoma: a second look.

Authors:  K Ramm; I B Vergote; J Kaern; C G Tropé
Journal:  Gynecol Oncol       Date:  1992-08       Impact factor: 5.482

9.  Treatment of metastatic and recurrent cervix cancer with chemotherapy: a randomised trial comparing hydroxyurea with cisdiamminedichloro-platinum plus methotrexate.

Authors:  W R Bezwoda; M Nissenbaum; D P Derman
Journal:  Med Pediatr Oncol       Date:  1986

10.  Phase II study of esorubicin (4'-deoxydoxorubicin) in advanced or metastatic squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group Study.

Authors:  W P McGuire; J A Blessing; E Yordan; J Beecham
Journal:  Invest New Drugs       Date:  1989-07       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.